Elixir Capital Ltd Q2 FY26 – When a Research House Needs Research on Itself: Wild Swings, Vanishing Profits & A Book Value Bargain!
1. At a Glance
Welcome to the wild world of Elixir Capital Ltd (BSE: 531278) — a company that claims to research the market but may need to research what’s happening in its own books. The stock, trading at ₹98.3, has fallen from its high of ₹351, currently hovering at 0.95x book value, which is as close as you can get to telling investors, “Hey, I’m literally worth what my books say, no premium, no drama.”
Market cap? A modest ₹57 crore. Quarterly sales at ₹11.1 crore, down a dramatic 40% QoQ, and profits have dropped a heart-stopping 79.6%. The company that once flaunted ROE of 18% and ROCE of 20.1% now posted a net loss of ₹0.71 crore on a TTM basis. Still, promoters aren’t leaving the sinking ship — 71.3% of the company remains in family hands.
And for those who live for dividend income, Elixir does throw a bone — a 1.27% dividend yield, which is like getting a chai per share every year.
So, is Elixir Capital the philosopher king of the small-cap world, or just another portfolio manager who forgot to manage its own? Buckle up, this one’s spicy.
2. Introduction
Once upon a Dalal Street afternoon in 1994, Elixir Capital Ltd was born — a brainchild meant to blend the mystique of research, investment, and capital markets into one potent potion. Fast forward 30 years, and the name “Elixir” sounds a bit ironic for investors who’ve lost 66% in a single year.
The company prides itself on “investing in shares and securities and providing services of capital market research and analysis.” Translation? They buy stocks, sell stocks, and tell others how to buy and sell stocks — the holy trinity of every broking outfit that ever existed in South Mumbai.
But Elixir isn’t just a one-trick pony. Through its subsidiaries, it runs stockbroking, portfolio management, depository services, and even a commodities arm. In short, if it’s tradable and volatile, Elixir’s fingerprints are on it.
And yet, the Q2 FY26 results tell a different story. Revenue dropped by 40%, PAT fell 79%, and EPS crashed from ₹4.70 to ₹2.95. When your business is understanding the market, those numbers feel like getting schooled by your own student.
Still, it’s hard not to admire the Mehta family’s consistency — whether the market is booming or bleeding, their 71.3% promoter holding stands rock solid, unpledged, untouched.
3. Business Model – WTF Do They Even Do?
If you’re thinking Elixir makes potions, relax — this is no Hogwarts. Elixir Capital is an investment holding and broking conglomerate that earns its keep through trading, arbitrage, portfolio management, and capital market services.
Let’s break it down:
Parent company (Elixir Capital Ltd): Handles proprietary investments, market research, and securities trading. Essentially, the “thinking” arm of the group.
Subsidiary (Elixir Equities Pvt. Ltd.): A SEBI-registered stockbroker, depository participant (CDSL), and portfolio manager. The “doing” arm.
Step-down subsidiary (Dipan Mehta Commodities Pvt. Ltd.): Trades in commodities via MCX. Because why not diversify your volatility?
Another step-down subsidiary (Elixir Wealth Management Pvt. Ltd.): Focused on wealth management, for people who still have wealth left.
The business makes money from:
Trading income (a whopping 88% of FY22 revenue)
Portfolio management and depository fees
Dividends and interest income
Think of Elixir as the “research and trade” factory — but lately, its trades seem to be researching loss-making patterns.
4. Financials Overview
Quarterly Results Locked: Q2 FY26
Metric
Latest Qtr (Sep 2025)
YoY Qtr (Sep 2024)
Prev Qtr (Jun 2025)
YoY %
QoQ %
Revenue
₹11.09 Cr
₹18.56 Cr
₹10.92 Cr
-40.2%
1.6%
EBITDA
₹4.47 Cr
₹15.56 Cr
₹4.25 Cr
-71.3%
5.2%
PAT
₹2.31 Cr
₹11.30 Cr
₹3.69 Cr
-79.6%
-37.4%
EPS (₹)
2.95
14.41
4.70
-79.5%
-37.2%
The only thing positive here is that EBITDA and revenue didn’t collapse completely. But YoY, this is a massacre. PAT shrank nearly 80%, revenue down 40%, and the once-impressive OPM above 80% has dropped to 40.3% — still healthy, but clearly suffering.
For a company whose business is literally reading balance sheets, this one feels like they skipped their own.
5. Valuation Discussion – Fair Value Range
Let’s crunch some educational numbers.
CMP: ₹98.3
Book Value: ₹104
TTM EPS: ₹-1.64 (loss-making TTM, but profitable in Q2)
Annualized EPS (Q2 * 4): 2.95 × 4 = ₹11.8
P/E Range:
CMP ÷ Annualized EPS = 98.3 ÷ 11.8 = 8.3x
Assuming a fair industry multiple between 10x–15x, the educational fair value range lies between ₹118–₹177 per share.
